Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.85 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 6.4× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 64 Days on average.
| RGEN | VCIT | |
|---|---|---|
Market Cap | $11.31B | $72.20B |
Volume | 1,216,919 | 13,245,117 |
Sector | Health | Fixed Income |
52-Week High | $194.57 | $84.82 |
52-Week Low | $102.87 | $77.98 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $11.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $78.48, down 0.03% on the day. The technical outlook is mixed with a bullish overall signal but bearish moving averages, while fundamentals are supported by a 4.8% yield and low 0.03% expense ratio. Recent news highlights institutional buying and favorable comparisons to peer bond ETFs.
The outlook for VCIT is positive for income-focused investors seeking corporate bond exposure with low costs. Key opportunities include attractive yield and institutional interest, while risks involve interest rate sensitivity and credit spread volatility in the corporate bond market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
